Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-250 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof, a buffer, a stabilizer, a surfactant, and an antioxidant in the amounts specified herein. In particular embodiments, the anti-PD-1 antibody is pembrolizumab. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

Abstract: A syringe holder for holding and stabilizing syringes, the syringe holder comprising a base, and both a vertical mount and a horizontal mount extending from one side of the base. The vertical mount comprises a cylindrical cavity configured to receive and rotatably attach the syringe to the base such that the syringe is held to the base in a generally vertical orientation, while the horizontal mount comprises a lower barrel support and an upper barrel support configured to receive and rotatably attach the bottom end of the barrel and the top end of the barrel of the syringe to the base such that the syringe is held to the base in a generally horizontal orientation. In both orientations, the syringe holder of the present invention provides easy access to most of the exterior surfaces of the syringes and reduces safety hazards associated with creating sample defects on syringes for purposes of qualification testing for syringe inspectors.

Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: A vial holder for holding and stabilizing vials, the vial holder comprising a base, and both a vertical mount and a horizontal mount extending from one side of the base. The vertical mount comprises a cylindrical cavity configured to receive and rotatably attach the vial to the base such that the vial is held to the base in a generally vertical orientation, while the horizontal mount comprises a body support and a neck support configured to receive and rotatably attach the body and the neck of the vial to the base such that the vial is held to the base in a generally horizontal orientation. In both orientations, the vial holder of the present invention provides easy access to most of the exterior surfaces of the vials and reduces safety hazards associated with creating sample defects on vials for purposes of qualification testing for vial inspectors.

Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.

Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

Abstract: The present invention relates to a nanoparticle and a composition comprising a nanoparticle.

Abstract: The present invention relates to excipients for special protein formulations, which are suitable to improve the thermal stability against denaturation and deactivation. In particular, the present invention relates to additives for thermostabilizing of vaccine formulations.

Abstract: The invention relates to quinoxaline derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.

Abstract: The present invention relates to processes for separating mixtures containing enantiomers of metal complexes with aromatic and/or heteroaromatic ligands, to metal complexes and to electronic devices, especially organic electroluminescent devices, comprising these metal complexes.

Abstract: A switchable optical device is provided having a first substrate (11), a second substrate (12) and a seal (114). The two substrates (11, 12) and the seal (114) are arranged such that a cell having a cell gap is formed and a switchable medium (10) is located inside the cell gap. The first substrate (11) has a first transparent electrode (21) and the second substrate (12) has a second transparent electrode (22). The electrodes (21, 22) are facing towards the cell gap. The two substrates (11, 12) are arranged such that the first substrate (11) has a first region (71) adjacent to a first edge (41) of the first substrate (11) which does not overlap with the second substrate (12) and the second substrate (12) has a second region (72) which does not overlap with the first substrate (11). A first electrically conducting busbar (31) is arranged in the first region (71) and a second electrically conducting busbar (32) is arranged in the second region (72).

Abstract: The invention relates to compounds of the formula I, in which R, A, n, L1, L2, L3 and X have the meanings given in Claim 1, to a process for their preparation, and to liquid-crystalline media comprising at least one compound of the formula I and electro-optical displays containing a liquid-crystalline medium of this type.

Abstract: The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.

Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerisable compound, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.

Abstract: The present invention relates to the compounds of the formulae (1) and (2) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.

Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.